A multiple dose powderinhaler (Turbuhaler®) compared with a conventional aerosol

Publisher Website
Google Scholar
Abstract
Nineteen patients with asthma completed an open, randomized, crossover study in which 0.5 mg terbutaline sulphate was administered either via Turbuhaler or via the metered dose inhaler (MDI) for 2-week periods. The clinical effect of the two treatment forms was comparable; both provided adequate bronchodilator therapy. Patients also considered Turbuhaler and MDI equally effective, with a small preference for the MDI. Turbuhaler seems to be a valuable alternative to bronchodilator MDI therapy. This study showed equipotent bronchodilatory efficacy from terbutaline sulphate when administered via Turbuhaler and via MDI. Additional advantages of Turbuhaler, such as absence of coordination problems and additives, make it an attractive alternative in the daily treatment of asthma.